jRCT1032220442招募中不适用
Endoscopic ultrasound versus 3.0-Tesla magnetic resonance cholangiopancreatography for the diagnosis of computed tomography-negative common bile duct stone: randomized controlled trial
未提供0 个研究点目标入组 90 人开始时间: 2022年11月22日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 90
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Diagnostic Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •20 years of age or older.
- •Met the diagnostic criteria for suspected or definite acute cholangitis of mild or moderate severity according to TG18 despite negative CT results for choledocholithiasis.
- •Provided written informed consent.
排除标准
- •Patients with claustrophobia.
- •Patients with non-MRI compatible metal implants.
- •Patients who have an altered or postsurgical upper gastrointestinal anatomy.
- •Pregnant or lactating women.
- •Patients with severe acute cholangitis as per the TG18 guideline.
- •Patients otherwise deemed unfit by the investigators based on their clinical judgment.
结局指标
主要结局
-
diagnostic accuracy
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Phase 3 Clinical Trial with MD-0901JPRN-jRCT2080222425MOCHIDA PHARMACEUTICAL CO., LTD.250
招募中
3 期
on-inferiority clinical trial to compare efficacy and safety of Pembrolizumab (CinnaGen Co.) versus Keytruda® in patients with metastatic Non-Small Cell Lung Cancer (NSCLC)IRCT20150303021315N29CinnaGen company295
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
进行中（未招募）
3 期
Selective use of postoperative radiotherapy after mastectomy (SUPREMO)Breast CancerACTRN12612000407897nited Kingdom (UK) Medical Research Council (MRC)1,600
进行中（未招募）
不适用
NCCH2201/MK013 trial (CRYSTAL trial)jRCT203122052920